试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
编号:NCT05161936登记状态:提前终止企业 / 申办者:Alnylam Pharmaceuticals
药物 / 成分:Lumasiran、Placebo
登记的停止原因(原文):Study terminated early due to low enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects
编号:NCT05559125登记状态:提前终止企业 / 申办者:Staidson (Beijing) Biopharmaceuticals Co., Ltd
药物 / 成分:STSA-1002 Injection、STSA-1005 Injection
登记的停止原因(原文):Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-21
Study of A Long Lasting Local Anesthestic for Hand, Wrist or Finger Surgery
编号:NCT02058303登记状态:提前终止企业 / 申办者:Jose Soberon, MD
药物 / 成分:Exparel Forearm block、Bupivacaine supraclavicular block
登记的停止原因(原文):PI leaving instutition
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-21
Exparel as a Nerve Block for Severe Hand Pain
编号:NCT02374320登记状态:提前终止企业 / 申办者:Jose Soberon, MD
药物 / 成分:liposomal bupivacaine
登记的停止原因(原文):PI leaving institution
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-21
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
编号:NCT03175978登记状态:提前终止企业 / 申办者:IGF Oncology, LLC
药物 / 成分:IGF/MTX
登记的停止原因(原文):Funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-21
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
编号:NCT04190628登记状态:提前终止企业 / 申办者:ABM Therapeutics Corporation
药物 / 成分:ABM-1310、Cobimetinib
登记的停止原因(原文):Not related to safety concerns or lack of efficacy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-21
The Effects of Low Dose Ketamine on Cardiovascular Function
编号:NCT04429685登记状态:提前终止企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:Ketamine、Saline (placebo)
登记的停止原因(原文):The focus of the laboratory went a different direction given extramural funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-21
A Study of EMB-02 in Participants With Advanced Solid Tumors
编号:NCT04618393登记状态:提前终止企业 / 申办者:Shanghai EpimAb Biotherapeutics Co., Ltd.
药物 / 成分:EMB-02
登记的停止原因(原文):Company's resource optimization and product's development change
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-21
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
编号:NCT04698915登记状态:提前终止企业 / 申办者:Galera Therapeutics, Inc.
药物 / 成分:Drug GC4711、Placebo
登记的停止原因(原文):Futility Analysis
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-21
A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients
编号:NCT05075304登记状态:提前终止企业 / 申办者:Staidson (Beijing) Biopharmaceuticals Co., Ltd
药物 / 成分:BDB-001 injection、BDB-001 injection、BDB-001 injection
登记的停止原因(原文):Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.
查看官方原始记录 ↗